Altintaş Handan, Ateş Oznur, Uyde-Doğan B Sönmez, Alp F Ilkay, Kaleli Deniz, Ozdemir Osman, Birteksöz Seher, Otük Gülten, Atana Dilek, Uzun Meltem
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Arzneimittelforschung. 2006;56(3):239-48.
In the present study, 20 new compounds having 3-[2-(5-aryl-1,3,4-oxadiazol-2-yl) imino-4-thiazolidinon-5-ylidene]-5-substituted/nonsubstituted 1H-indole-2-one (I-XII) and 3-[2-(4-carbethoxymethylthiazol-2-yl)imino-4-thiazoldinon-5-ylidenel-5-substituted/nonsubstituted IH-indole-2-one (XIII-XX) systems were synthesized. The structures were confirmed by spectral methods (UV, IR, 1H-NMR, 13C-NMR, 13C-DEPT (135), electron impact mass spectrometry) and elemental analysis. All compounds were tested for in vitro antimicrobial activity against Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC 12228, Escherichia coli ATCC 8739, Klebsiella pneumoniae ATCC 4352, Pseudomonas aeruginosa ATCC 1539, Salmonella typhi, Shigella flexneri, Proteus mirabilis ATCC 14153, Candida albicans ATCC 10231, Microsporum gypseum (NCPF-580), Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum and some of them were found to be active. Especially, compound I was more active than cefuroxime sodium (CAS 56238-63-2) which was used as a standard, and the activity of compound XII was close to that of cefuroxime sodium against Staphylococcus epidermidis ATCC 12228. Primary screening for antituberculous activity was conducted at 6.25 microg/ml against Mycobacterium tuberculosis H37Rv in BACTEC 12B medium using the BACTEC 460 radiometric system. The anticonvulsant activities of selected prototoype compounds (I, IV-VI, VIII, XI, XIII, XVI-XVIII) administered at doses of 50-200 mg/kg (i.p.) were evaluated using the pentetrazol test (PTZ) in mice.
在本研究中,合成了20种具有3-[2-(5-芳基-1,3,4-恶二唑-2-基)亚氨基-4-噻唑烷酮-5-亚基]-5-取代/未取代的1H-吲哚-2-酮(I-XII)和3-[2-(4-乙氧羰基甲基噻唑-2-基)亚氨基-4-噻唑烷酮-5-亚基]-5-取代/未取代的1H-吲哚-2-酮(XIII-XX)体系的新化合物。通过光谱方法(紫外光谱、红外光谱、1H-核磁共振、13C-核磁共振、13C-DEPT(135)、电子轰击质谱)和元素分析确定了结构。对所有化合物进行了针对金黄色葡萄球菌ATCC 6538、表皮葡萄球菌ATCC 12228、大肠杆菌ATCC 8739、肺炎克雷伯菌ATCC 4352、铜绿假单胞菌ATCC 1539、伤寒沙门氏菌、福氏志贺氏菌、奇异变形杆菌ATCC 14153、白色念珠菌ATCC 10231、石膏样小孢子菌(NCPF-580)、犬小孢子菌、须癣毛癣菌和红色毛癣菌的体外抗菌活性测试,发现其中一些具有活性。特别是,化合物I比用作标准的头孢呋辛钠(CAS 56238-63-2)活性更高,并且化合物XII对表皮葡萄球菌ATCC 12228的活性与头孢呋辛钠相近。使用BACTEC 460放射性系统在BACTEC 12B培养基中以6.25微克/毫升的浓度对结核分枝杆菌H37Rv进行抗结核活性的初步筛选。使用小鼠戊四氮试验(PTZ)评估了以50-200毫克/千克(腹腔注射)剂量给药的选定原型化合物(I、IV-VI、VIII、XI、XIII、XVI-XVIII)的抗惊厥活性。